The outbreak of Covid-19 ushered the world into utter chaos, followed by continuous fear. Pharma giants rushed to make a viable vaccine for the virus
The stock of Novavax Inc (NVAX) followed a bearish pattern in the after-market after releasing its financial outlook for Q4 and FY21. In the after-market,
Novavax, Inc. (NVAX) gained a further 9.56% at $238.10 premarket, at the last check on Monday. The stock has been gaining on the news of
Things are getting interesting in the COVID-19 vaccine space. Pharmaceutical firms are fighting against the global pandemic. Big US pharma’s who are part of this
Change is inevitable in every aspect of life because it results from human exploration and applying knowledge to improve life quality. This is why many
Novavax, Inc. (NVAX) stock prices were up by a marginal 2.31% as of the market closing on June 11th, 2021, bringing the price per share
Due to the spread of the coronavirus pandemic all over the world Biotech stocks have gained great attention in the market. There is great competition
Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter
This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country,
Novavax Inc’s (NVAX) stock was up 1.73% to trade at $125.6 in the premarket session today, despite the recent news that the company has again
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.